Results 21 to 30 of about 19,412 (203)

APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas. [PDF]

, 2022
BACKGROUND Studies of targeted therapy resistance in lung cancer have primarily focused on single gene alterations. Based on prior work implicating APOBEC mutagenesis in histological transformation of EGFR-mutant lung cancers, we hypothesized that ...
Choudhury, N J, Patel, J, Berger, M F, Chandarlapaty, S, Ng, C K Y, Lovly, C M, Zhang, Y-K, Heller, G, Gazzo, A, Ladanyi, M, Marra, A, Pei, X, Reis-Filho, J S, Yu, H A, Selenica, P, Rudin, C M, Falcon, C J, Curry, M, Zhu, Y   +18 more
core   +2 more sources

Successful treatment with afatinib following the failure of osimertinib rechallenge with osimertinib-induced interstitial lung disease: A case report

Respiratory Medicine Case Reports, 2021
Herein, we report the case of an 84-year-old woman with epidermal growth factor receptor (EGFR) mutation exon 19 deletion postoperative recurrent lung adenocarcinoma.
Yozo Sato, Akimasa Sekine, Eri Hagiwara, Midori Sato, Takafumi Yamaya, Masato Asaoka, Katsuyuki Higa, Satoshi Ikeda, Tomohisa Baba, Shigeru Komatsu, Tae Iwasawa, Takashi Ogura   +11 more
doaj   +1 more source

Population Pharmacokinetics and Exposure-Response Analyses of Savolitinib Alone or in Combination With Osimertinib in Patients With Locally Advanced or Metastatic Solid Tumors. [PDF]

Clin Transl Sci
ABSTRACT Savolitinib (ORPATHYS) is an oral, highly selective inhibitor of the mesenchymal–epithelial transition (MET) receptor tyrosine kinase that has demonstrated clinical activity across multiple advanced solid tumors. A comprehensive population pharmacokinetics analysis using cumulative data from 998 patients across 10 clinical studies ...
Shahraz A, Derippe T, Kode KK, Allmond J, Nelson S, Igwegbe I, Sawant-Basak A, Vishwanathan K, Miah K.   +8 more
europepmc   +2 more sources

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors [PDF]

, 2017
Non-small cell lung cancer (NSCLC) driven by activating mutations in epidermal growth factor receptor (EGFR) constitutes up to 10% of NSCLC cases. According to the NCCN recommendations, all patients (with the exception of smoking patients with squamous ...
Marcin Skrzypski, Amelia Szymanowska-Narloch, Rafał Dziadziuszko   +2 more
core   +1 more source

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

Journal of Experimental & Clinical Cancer Research, 2017
Background Osimertinib is a third-generation EGFR-TKI with a high selective potency against T790M-mutant NSCLC patients. Considering that osimertinib can lead to enhanced HER-2 expression on cell surface and HER-2 overexpression is a mechanism of ...
Silvia La Monica, Daniele Cretella, Mara Bonelli, Claudia Fumarola, Andrea Cavazzoni, Graziana Digiacomo, Lisa Flammini, Elisabetta Barocelli, Roberta Minari, Nadia Naldi, Pier Giorgio Petronini, Marcello Tiseo, Roberta Alfieri   +12 more
doaj   +1 more source

Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation

Respiratory Research, 2021
Background This study was designed to investigate the difference between brain metastases (BM) and non-brain metastases (non-BM) treated by osimertinib in advanced patients with an acquired EGFR T790M mutation after obtaining first-generation EGFR-TKI ...
Changhui Li, Wei Nie, Jingdong Guo, Anning Xiong, Hua Zhong, Tianqing Chu, Runbo Zhong, Jianlin Xu, Jun Lu, Xiaoxuan Zheng, Bo Zhang, Yinchen Shen, Feng Pan, Baohui Han, Xueyan Zhang   +14 more
doaj   +1 more source

Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer [PDF]

, 2017
BACKGROUND\ud \ud Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in patients with non–small-cell lung cancer.
Mann, H., Ahn, M.-J., Mok, T.S., Theelen, W.S.M.E., He, Y., O'Byrne, Kenneth J., Garassino, M.C., Papadimitrakopoulou, V.A., Templeton, A., Ramalingam, S.S., Shepherd, F.A., Ghiorghiu, S., Akamatsu, H., Sebastian, M., Marotti, M., Lee, C.K., Wu, Y.-L., Kim, H. R.   +17 more
core   +1 more source

Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines [PDF]

, 2020
Background: Osimertinib improve therapy for non-small cell lung cancer (NSCLC). However, invariable acquired resistance appears. Methods: MTT assay was used to analyze cell viability. Protein expression and activation was detected by Western blotting. In
Bracht, Jillian Willhelmina Paulina, Ito, Masaoki, Codony Servat, Carles, Rosell, Rafael, Molina Vila, Miguel Angel, Karachaliou, Niki, Viteri, Santiago, Berenguer, Jordi, Codony Servat, Jordi, Chaib, Imane   +9 more
core   +1 more source

Analysis of adverse drug reactions of Osimertinib in the 2nd‐line treatment of EGFR mutant advanced nonsmall cell lung cancer

Precision Medical Sciences, 2022
The aim was to analyze the clinical characteristics of adverse drug reactions (ADRs) induced by Osimertinib and their effects on the prognosis, so as to further provide reference for clinical medication.
Yingying Jiang, Yue Shi, Zihan Wang, Hang Li, Zhitong Wang, Kang He, Yuxin Ma, Jingjing Xue, Yumeng Shi, Jianwei Lu, Meiqi Shi, Bo Shen, Guoren Zhou, Xiaohua Wang, Cheng Chen, Jifeng Feng   +15 more
doaj   +1 more source

Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review

Frontiers in Oncology, 2021
Introduction: Small cell lung cancer (SCLC) transformation represents a mechanism of resistance to osimertinib in EGFR-mutated lung adenocarcinoma, which dramatically impacts patients' prognosis due to high refractoriness to conventional treatments.Case ...
Alessandro Leonetti, Roberta Minari, Giulia Mazzaschi, Letizia Gnetti, Silvia La Monica, Roberta Alfieri, Nicoletta Campanini, Michela Verzè, Andrea Olivani, Luigi Ventura, Marcello Tiseo, Marcello Tiseo   +11 more
doaj   +1 more source